Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Lonestar Capital Management Boosts Stake In Westmoreland Coal Company (WLB)

Jerome L. Simon is bullish on Westmoreland Coal Company (NASDAQ:WLB) and has increased his fund’s investment in this company. Lonestar Capital Management has revealed an addition of 400,000 shares to its stake, taking it to 900,000 shares, as reported in a recent filing with the Securities and Exchange Commission. The current position gives Simon and Lonestar Capital control over 5.4% of the company’s common stock.

Westmoreland Coal Company (WLB)

Jim Simons is also a fan of Westmoreland Coal Company (NASDAQ:WLB) and has increased his fund’s stake in the company by 109% during Q1 of 2014. Renaissance Technologies has reported ownership of approximately 333,300 shares in its latest 13F filing. Corsair Capital Management, run by Jay Petschek and Steven Major, has disclosed a 17% increase in its holding of this stock to approximately 192,500 shares at the end of the first quarter. Nelson Obus and his fund, Wynnefield Capital, have made Westmoreland Coal Company (NASDAQ:WLB) an important equity investment, which accounts for 6.69% of their portfolio. However, Obus had decided to reduce his exposure by 38% to 460,400 shares during the same period of time.

Disclosure. none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!